Bio-Path Holdings provided updates on two clinical trials: BP1001-A for solid tumors and prexigebersen for acute myeloid leukemia (AML). A patient with gynecologic cancer in the BP1001-A trial experienced tumor reduction and stable disease after multiple rounds of treatment. Two elderly AML patients in the prexigebersen trial remain in complete remission after two years.
The positive results from the BP1001-A trial are particularly encouraging given the patient’s advanced stage of cancer and prior unsuccessful treatments. This suggests that BP1001-A could offer a new treatment option for patients with advanced solid tumors who have exhausted other therapies. The extended remission observed in the AML patients highlights the potential of prexigebersen to improve long-term outcomes, especially for elderly patients who often cannot tolerate intensive chemotherapy.
The BP1001-A trial is a Phase 1/1b study, currently evaluating the drug as a monotherapy at increasing dose levels. Future phases will explore BP1001-A in combination with other chemotherapies for specific tumor types. The prexigebersen trial is a Phase 2 study evaluating the drug in combination with decitabine and venetoclax for AML.
The continued positive data from these trials strengthen the potential of Bio-Path’s DNAbilize platform and its pipeline of targeted cancer therapies. The data suggests a possible path forward for patients with limited treatment options and underscores the potential for improved efficacy and tolerability compared to current standards of care. Further research will be crucial to confirm these early findings and explore the full potential of these drug candidates in broader patient populations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
